AngloGold Ashanti Limited vs Charles River Laboratories Intl. Inc — how do they compare? AngloGold Ashanti Limited trades at $98.04 (market cap $49.28B), while Charles River Laboratories Intl. Inc trades at $286.51 (market cap $13.46B). The key difference: AngloGold Ashanti Limited is far larger — about 3.7× Charles River Laboratories Intl. Inc's market cap, and AngloGold Ashanti Limited pays a 4.64% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AU | CRL | |
|---|---|---|
Market Cap | $49.28B | $13.46B |
Sector | Basic Materials | Health |
52-Week High | $128.26 | $282.00 |
52-Week Low | $52.15 | $145.57 |
Enterprise Value | $48.29B | $16.30B |
Dividend Yield | 4.64% | — |
Signals from Pluang's Aura AI — not financial advice
AngloGold Ashanti (AU) trades at $98.20, up 0.98% today, near its 52-week high. The stock shows strong fundamental momentum with revenue surging to $9.89B in 2025 and net income reaching $2.64B. Analysts maintain a bullish consensus with a $120.33 price target, supported by robust cash flow and a $2B buyback program. Technical indicators are mixed, with moving averages bullish but RSI levels suggesting overbought conditions. Recent news highlights operational strength and institutional accumulation.
Outlook remains positive driven by gold price strength and production growth, but risks include commodity volatility and operational execution. The stock offers value with a P/E of 13.06 and high profitability margins, though overbought technicals may prompt near-term consolidation. Investor sentiment is favorable, but macroeconomic factors could impact performance.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Trailing returns across standard periods
Anglogold Ashanti Ltd is one of the largest gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from Africa which includes Ghana, Guinea, Mali, the Democratic Republic of the Congo, and Tanzania.
Read more on AU →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →